» Articles » PMID: 9855154

Occlusive Ligature and Standardized Fenestration of a Baerveldt Tube with and Without Antimetabolites for Early Postoperative Intraocular Pressure Control

Overview
Journal Ophthalmology
Publisher Elsevier
Specialty Ophthalmology
Date 1998 Dec 17
PMID 9855154
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine the effectiveness of a surgical modification for a nonvalved aqueous tube shunt in controlling intraocular pressure (IOP) in the early postoperative period. The effect of antimetabolite use on IOP also was studied.

Design: A retrospective study of consecutive patients who underwent modified Baerveldt 350-mm2 implant with varied, nonrandomized, exposure to antimetabolites.

Participants: Fifty-one eyes of 46 patients with uncontrolled glaucoma were examined.

Intervention: Identical surgical modification of a Baerveldt 350-mm2 tube was performed in all cases and consisted of placement of an occlusive 7-0 polyglactin suture just anterior to the plate followed by a through-and-through penetration of the tube just anterior to the occlusive ligature with a standardized 15 degrees blade. Seventeen eyes were not exposed to antimetabolite, while 2 groups of 17 eyes had 3 minutes' episcleral exposure to either 5-fluorouracil 50 mg/ml or mitomycin C 0.4 mg/ml at the location corresponding to the fenestration. The Tenon's layer and conjunctiva were not exposed because of concerns regarding conjunctival erosion over the device.

Main Outcome Measure: Intraocular pressure and number of antiglaucoma medications required were analyzed.

Results: For the group, mean IOP before surgery and on postoperative days 1, 4, 10, 21, 42, 63, 84, and 112 was (in millimeters of mercury) 34.6, 20.1, 17.0, 17.2, 22.0, 17.3, 18.7, 17.4, and 15.6, respectively. There was an elevation of IOP at day 21 relative to fibrotic blockage of the fenestration before suture autolysis. This was temporized with antiglaucoma medication until suture autolysis occurred or treated with laser suture lysis (8 eyes). On day 1, hypotony occurred in 3 (6%) eyes whereas IOP greater than 30 mmHg was observed in 13 (26%) eyes. By day 10, the frequency had decreased to one (2.1 %) eye and three (6.4%) eyes, respectively. The use of antimetabolites did not result in lower IOP or less medication needed for any group at any interval (analysis of variance).

Conclusion: This modification of a nonvalved glaucoma tube shunt device provides adequate IOP control in the early postoperative period with a low rate of hypotony and surgical complications. If elevation of IOP occurs before suture autolysis, it generally is well controlled by antiglaucoma medications or laser suture lysis. Antimetabolite exposure did not influence early postoperative IOP in this study.

Citing Articles

Impact of the restrictive technique on outcomes in Baerveldt-350 implant surgery.

Segura-Duch G, Oliver-Gutierrez D, Duch S, Schilt M, Arciniegas-Perasso C BMJ Open Ophthalmol. 2025; 10(1).

PMID: 39947710 PMC: 11831295. DOI: 10.1136/bmjophth-2024-001879.


Evaluating the Safety and Efficacy of a Novel Glaucoma Drainage Device in High-Risk Adult Glaucoma Patients: A One-Year Pilot Study.

Ahmed F, Normando E, Ahmed S, Virdee S, Al-Nahrawy A J Clin Med. 2024; 13(17).

PMID: 39274211 PMC: 11396561. DOI: 10.3390/jcm13174996.


Surgical safety and efficacy of a multi-stent system, the comet stent, in Baerveldt glaucoma implant surgery: a prospective pilot study.

Manabe S, Hirata A, Akagi T, Hayashi K Jpn J Ophthalmol. 2023; 67(6):685-692.

PMID: 37540326 DOI: 10.1007/s10384-023-01014-6.


Internal Tube Occlusion with An Easily Removable Non-Absorbable Double Suture: A Novel Surgical Technique Adjunct for Non-Valved Glaucoma Drainage Devices.

Savastano A, Gambini G, Savastano M, Carla M, Rizzo C, Caporossi T Vision (Basel). 2023; 7(1).

PMID: 36977294 PMC: 10057999. DOI: 10.3390/vision7010014.


Systematic Preserflo MicroShunt Intraluminal Stenting for Hypotony Prevention in Highly Myopic Patients: A Comparative Study.

Lupardi E, Laffi G, Moramarco A, Barboni P, Fontana L J Clin Med. 2023; 12(4).

PMID: 36836212 PMC: 9959075. DOI: 10.3390/jcm12041677.